UNILAG AD
  • The Membership Club
  • #EndSARS Dashboard
  • PT Hausa
  • About Us
  • Advert Rates
  • Careers
  • Contact Us
Saturday, August 20, 2022
Premium Times Nigeria
  • Home
  • Gender
  • News
    • Headline Stories
    • Top News
    • More News
    • Foreign
  • Investigations
  • Business
    • News Reports
    • Financial Inclusion
    • Analysis and Data
    • Business Specials
    • Opinion
    • Oil/Gas Reports
      • FAAC Reports
      • Revenue
  • Opinion
  • Health
    • News Reports
    • Special Reports and Investigations
      • Health Specials
    • Features and Interviews
    • Multimedia
    • Primary Health Tracker
  • Agriculture
    • News Report
    • Special Reports/Investigations
    • Features and Interviews
    • Multimedia
  • Arts/Life
    • Arts/Books
    • Kannywood
    • Lifestyle
    • Music
    • Nollywood
    • Travel
  • Sports
    • Football
    • More Sports News
    • Sports Features
  • Projects
    • #EndSARS Dashboard
    • Parliament Watch
    • #PandoraPapers
    • Panama Papers
    • Paradise Papers
    • AGAHRIN
  • AUN-PT Data Hub
  • Home
  • Gender
  • News
    • Headline Stories
    • Top News
    • More News
    • Foreign
  • Investigations
  • Business
    • News Reports
    • Financial Inclusion
    • Analysis and Data
    • Business Specials
    • Opinion
    • Oil/Gas Reports
      • FAAC Reports
      • Revenue
  • Opinion
  • Health
    • News Reports
    • Special Reports and Investigations
      • Health Specials
    • Features and Interviews
    • Multimedia
    • Primary Health Tracker
  • Agriculture
    • News Report
    • Special Reports/Investigations
    • Features and Interviews
    • Multimedia
  • Arts/Life
    • Arts/Books
    • Kannywood
    • Lifestyle
    • Music
    • Nollywood
    • Travel
  • Sports
    • Football
    • More Sports News
    • Sports Features
  • Projects
    • #EndSARS Dashboard
    • Parliament Watch
    • #PandoraPapers
    • Panama Papers
    • Paradise Papers
    • AGAHRIN
  • AUN-PT Data Hub
Premium Times Nigeria
BUA Group Ad BUA Group Ad BUA Group Ad
Pills used to illustrate the story.

Pills used to illustrate the story.

Alarming levels of drug-resistant tuberculosis found worldwide

August 30, 2012
Reading Time: 3 mins read
0

The data emanating from several countries show that there is a hike in drug-resistant TB which can cost 200% more to treat.

Scientists have found an alarming number of cases of the lung disease, tuberculosis (TB), in Africa, Asia, Europe and Latin America, that are resistant to at least four powerful antibiotics.

In a large international study published in the Lancet medical journal on Thursday, researchers found rates of both multi drug-resistant TB (MDR-TB) and extensively drug-resistant TB (XDR-TB) were higher than previously thought.

The report also said the diseases are threatening global efforts to curb their spread.

“Most international recommendations for TB control have been developed for MDR-TB prevalence of up to around 5 per cent.

“Yet now we face prevalence up to 10 times higher in some places, where almost half of the patients are transmitting MDR strains,” Sven Hoffner of the Swedish Institute for Communicable Disease Control, said in a commentary on the study.

TB is already a worldwide pandemic that has infected 8.8 million people. It killed 1.4 million in 2010.

Drug-resistant TB is more difficult and costly to treat than normal TB, and is more often fatal.

MDR-TB is resistant to at least two first-line drugs – isoniazid and rifampicin – while XDR-TB is resistant to those two drugs as well as a powerful antibiotic type called a fluoroquinolone and a second-line injectable antibiotic.

TEXEM Advert

Treating even normal TB is a long process, with patients needing to take a cocktail of powerful antibiotics for six months. Many patients fail to complete their treatment correctly, a factor which has fuelled a rise in the drug-resistant forms.

Researchers who studied rates of the disease in Estonia, Latvia, Peru, the Philippines, Russia, South Africa, South Korea and Thailand found almost 44 per cent of cases of MDR TB were also resistant to at least one second-line drug.

Tom Evans, chief scientific officer at Aeras, a non-profit group working to develop new TB vaccines, told Reuters that treatment options for XDR-TB patients are “limited, expensive and toxic.”

Treatments for drug-resistant TB can cost 200 times more than those for normal TB, he said in an emailed statement. They can also cause severe side effects like deafness and psychosis, and can take two years to complete, he added.

In the U.S., MDR-TB treatment can cost 250,000 dollars or more per patient, and in many poorer countries costs can be catastrophic to health systems and patients’ families.

“Without a robust pipeline of new drugs to stay one step ahead, it will be nearly impossible to treat our way out of this epidemic,” Mr. Evans said.

Tracy Dalton from the U.S. Center for Disease Control and Prevention, who led the Lancet study, said that so far, XDR-TB has been reported in 77 countries worldwide.

“As more individuals are diagnosed with, and treated for, drug-resistant TB, more resistance to second-line drugs is expected to emerge,” she said.

The spread of these drug-resistant strains is “particularly worrisome” in areas with poor healthcare resources and limited access to effective drugs, she added.

TB is a bacterial infection that destroys patients’ lung tissue, making them cough and sneeze and spread germs through the air.

Experts say anyone with active TB can easily infect another 10 to 15 people a year.

The World Health Organisation (WHO) predicts more than two million people will contract MDR TB by 2015.

A report by non-governmental organisations in March said a $1.7 billion shortfall in funds to fight TB over the next five years meant 3.4 million patients would go untreated and gains made against the disease will be reversed.

In their research, Dalton and colleagues found rates of resistance varied widely between countries.

Overall, resistance to any second-line drug was detected in nearly 44 per cent of patients, ranging from 33 per cent in Thailand to 62 per cent in Latvia.

In about a fifth of cases, they found resistance to at least one second-line injectable drug.

This ranged from two per cent in the Philippines to 47 per cent in Latvia.

XDR-TB was found in 6.7 per cent of patients overall. Rates in South Korea, 15.2 per cent, and Russia 11.3 per cent, were more than twice the WHO’s global estimate of 5.4 per cent at that time.

  • Tweet
  • Email
  • Print
  • Telegram
  • More
  • WhatsApp
  • Share on Tumblr
  • Pocket


Support PREMIUM TIMES' journalism of integrity and credibility

Good journalism costs a lot of money. Yet only good journalism can ensure the possibility of a good society, an accountable democracy, and a transparent government.

For continued free access to the best investigative journalism in the country we ask you to consider making a modest support to this noble endeavour.

By contributing to PREMIUM TIMES, you are helping to sustain a journalism of relevance and ensuring it remains free and available to all.

Donate



TEXT AD: Call Willie - +2348098788999






PT Mag Campaign AD

Previous Post

Sambo in Tehran for Non-Aligned Movement summit

Next Post

Iniesta named Europe’s best

More News

CCTV Camera

Insecurity: Police call on Nigerians to install CCTV in business places, homes

August 19, 2022
Sheriff Oborevwori

Court of Appeal reserves judgement in Delta PDP governorship candidate’s suit

August 19, 2022
Emirates Airlines

Reps invite CBN Governor, Finance Minister over Emirates Airline’s planned suspension of flights

August 19, 2022
CrossRiverWatch publisher and journalist, Agba Jalingo. [PHOTO CREDIT: Crossriverwatch.com]

UPDATED: Police arrest journalist Agba Jalingo

August 19, 2022
Gunmen release additional four people

Train Attack: Gunmen release four more hostages, threaten to marry female victim

August 19, 2022
FILE PHOTO: LASTMA rank during an inspection

LASTMA apprehends two officers over illegal conduct

August 19, 2022
Leave Comment

Our Digital Network

  • PT Hausa
  • Election Centre
  • Human Trafficking Investigation
  • Centre for Investigative Journalism
  • National Conference
  • Press Attack Tracker
  • PT Academy
  • Dubawa
  • LeaksNG
  • Campus Reporter

Resources

  • Oil & Gas Facts
  • List of Universities in Nigeria
  • LIST: Federal Unity Colleges in Nigeria
  • NYSC Orientation Camps in Nigeria
  • Nigeria’s Federal/States’ Budgets since 2005
  • Malabu Scandal Thread
  • World Cup 2018
  • Panama Papers Game
  • Our Digital Network
  • About Us
  • Resources
  • Projects
  • Data & Infographics
  • DONATE

All content is Copyrighted © 2022 The Premium Times, Nigeria

No Result
View All Result
  • #PandoraPapers
  • Gender
  • News
    • Headline Stories
    • Top News
    • More News
    • Foreign
  • Investigations
  • Business
    • News Reports
    • Financial Inclusion
    • Analysis and Data
    • Business Specials
    • Opinion
    • Oil/Gas Reports
      • FAAC Reports
      • Revenue
  • Health
    • COVID-19
    • News Reports
    • Investigations
    • Data and Infographics
    • Health Specials
    • Features
    • Events
    • Primary Health Tracker
  • Agriculture
    • News Report
    • Research & Innovation
    • Data & Infographics
    • Special Reports/Investigations
    • Investigations
    • Interviews
    • Multimedia
  • Arts/Life
    • Arts/Books
    • Kannywood
    • Lifestyle
    • Music
    • Nollywood
    • Travel
  • Sports
    • Football
    • More Sports News
    • Sports Features
  • #EndSARS Dashboard
  • Projects
    • Panama Papers
    • Paradise Papers
    • Parliament Watch
    • AGAHRIN
  • AUN-PT Data Hub
  • Opinion
  • The Membership Club
  • DONATE
  • About Us
  • Advert Rates
  • PT Hausa
  • Dubawa NG
  • Careers
  • Contact Us
  • Digital Store

All content is Copyrighted © 2022 The Premium Times, Nigeria